332 Encinitas Boulevard
Suite 102
Encinitas, CA 92024
United States
858 224 9600
https://www.kiorapharma.com
版塊: Healthcare
行業: Biotechnology
全職員工:
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Brian M. Strem Ph.D. | President, CEO & Director | 429.23k | 無 | 1980 |
Dr. Eric J. Daniels M.B.A., M.D. | Chief Development Officer | 342.94k | 無 | 1974 |
Dr. Stefan Sperl Ph.D. | Executive Vice President of CMC & Operations | 無 | 無 | 無 |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
截至 無 止,Kiora Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。